Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 69.50 5,677 08:00:15
Bid Price Offer Price High Price Low Price Open Price
68.00 71.00 69.50 69.50 69.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.53 0.86 2.02 34.4 33
Last Trade Time Trade Type Trade Size Trade Price Currency
14:00:02 UT 598 70.00 GBX

Ixico (IXI) Latest News

More Ixico News
Ixico Investors    Ixico Takeover Rumours

Ixico (IXI) Discussions and Chat

Ixico Forums and Chat

Date Time Title Posts
21/7/202118:17Ixico PLC249
28/4/202112:03IXICO324

Add a New Thread

Ixico (IXI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ixico trades in real-time

Ixico (IXI) Top Chat Posts

DateSubject
01/8/2021
09:20
Ixico Daily Update: Ixico Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IXI. The last closing price for Ixico was 69.50p.
Ixico Plc has a 4 week average price of 66.50p and a 12 week average price of 66.50p.
The 1 year high share price is 124.75p while the 1 year low share price is currently 56p.
There are currently 47,969,521 shares in issue and the average daily traded volume is 21,214 shares. The market capitalisation of Ixico Plc is £33,338,817.10.
21/7/2021
18:17
shooting_star: Pretty damn quiet here, I've done a small top yesterday on the basis that the share is back below 70p. I figure that the valuation is attractive at this level...cash is £7m or about 14.5p per share, so I compute a trailing ex cash PE on 2020 EPS of roughly 27x. EV EBITDA on trailing 2020 numbers of about 19.8x? the descoped Huntington disease trials will impact near term - does anyone have a view on H2 revenues/profits? in any case they should win enough new business to eventually offset that setback?
26/5/2021
19:54
rocketblast: IXI latest results meeting can be viewed soon on the IXICO website. The meeting was well managed and their performance in my view was excellent and gave an excellent account of their strategy covering future roadmap and technology directions highlighting new Products and Services being in high demand. Their Cash flow was positive and growing. The future is very Bright and a strong company set of accounts were positive and clearly explained. It was important to listen to the message and clear answers to the questions put forward. I am topping up as much as is available. The management team are outstanding and will steer IXICO to great heights.
26/4/2021
07:43
michaelmouse: twitter @michae1mouse #IXI Strong trading update from IXICO this morning, and far less impact anticipated from ceased HD trial. Worst case was £7.7m now revised to £3.5m over 2 years. Order book up to £19m with cash at £7m. Growth in revs 8% in 1st half (£4.9m). Exciting growth story remains in tact.
16/4/2021
08:50
halfpenny: IXI with CIP support backs the move to 80/90p. Maybe news flow this weekend as new contracts start to flow. IXI should let their Products do the smart talking. Come on with news news news
12/4/2021
08:57
rcturner2: I hold shares in CIP, they have a good investment record and usually only hold a small number of companies (around 10) so that their investments make a material difference to the NAV. The main attraction currently is that the share price of CIP is 50p while the NAV is 80p, a massive discount.
31/3/2021
20:52
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast last week and IXI was one of the Stocks we discussed as Peter C3 himself holds it and it delivered up an unpleasant surprise. He talks about his strategy for what he intends to do next with IXI etc. Also in this episode we have a Special Guest Star in the form of Tim Rogers, who was the former CEO at ABDP. He gives loads of insights into the likely future for the Car Market and also gives some background etc. around ABDP. As always we also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Sadly we didn’t get time to chat about Tim’s classic motorcycle collection !! Anyway, if you use Youtube, Apple, Audioboom, Overcast, Google+ or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 45) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, with the intent being that it is like you are eavesdropping on us having a chat down the local boozer (we can dream !!). Cheers, WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-45-winning-stocks-tsla-vs-vow-bmy-abdp-hfd-pets-gaw-ixi-sdg-ai
26/8/2020
14:45
deltaham: Uptick in share price will be due to RNS at 1.55am today from Ixico on yesterday's Investor presentation "IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that a recording of the online Company presentation, delivered by Giulio Cerroni, Chief Executive Officer, and Grant Nash, Chief Finance Officer, on Tuesday 25 August, surrounding the Company's recent trading update, is now available to watch back on the Investor Meet Company platform. The Q&A has also been published following the meeting. "Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link, which will take you to the recording of the presentation and the Q&A: hxxps://www.investormeetcompany.com/ixico-plc/register-investor No new price-sensitive information is disclosed as part of the presentation."
16/3/2020
13:59
jpuff: IXICO plc IXICO announces expanded contract with VaccinexSource: RNS Non-RegulatoryTIDMIXIIXICO plc16 March 202016 March 2020IXICO plc("IXICO" or the "Company")IXICO announces an expanded contract for its imaging services with VaccinexSupports Vaccinex's diversification into clinical development of pepinemab for Alzheimer's diseaseIXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces an award of a contract to provide imaging services for Vaccinex Inc.'s (Nasdaq: VCNX) planned Phase Ib/IIa trial of pepinemab, a potential treatment of Alzheimer's disease (AD). This will build on the Company's existing contract to support Vaccinex's Phase II study of pepinemab in the Huntington's disease SIGNAL trial, which was previously announced in September 2017.Giulio Cerroni, Chief Executive Officer of IXICO, commented:"This AD trial, called SIGNAL - AD, is part of a new wave of investment in treatments for neurodegeneration by the global biopharmaceutical industry, with additional assets being brought through the pipeline thanks to the insights unlocked in earlier research programmes."We are delighted that Vaccinex has chosen to expand our partnership to support its diversification into Alzheimer's disease. Our existing project with Vaccinex, the SIGNAL trial, is in Huntington's disease (HD) to study the safety and efficacy of pepinemab, where the positive imaging results obtained in an interim cohort analysis indicated its potential in additional therapeutic areas; this contract was initiated in 2017 and the new award is a great testament to the achievements of our two organisations working diligently together since then. We are pleased to be part of Vaccinex's effort to bring hope to AD patients and their families."This contract does not have significant impact on management's expectations of perfomance for the year.For further information please contact: IXICO plc +44 (0) 20 3763 7498 Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer Optimum Strategic Communications +44 (0) 203 950 9144 Mary Clark, Supriya Mathur, Manel Mateus IXICO@optimumcomms.com About IXICOIXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.More information is available on www.IXICO.comAbout Vaccinex, Inc.Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in non-small cell lung cancer and Huntington's disease. Vaccinex is based in Rochester, New York.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNRABSGDXIXBDGGX(END) Dow Jones NewswiresMarch 16, 2020 05:00 ET (09:00 GMT)
17/2/2020
15:45
martinthebrave: Simon Thompson 12th December 2019 - "BUY" Annual results from Aim-traded IXICO (IXI:68p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans were materially better than I had anticipated when I recommended buying the shares, at 33p, in the summer ('Alpha Report: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). Having upgraded his earnings forecasts twice since then, analyst Chris Donnellan at house broker Cenkos Securities has done so again on the back of the latest results, highlighting the ongoing strong momentum in the business. The scans – magnetic resonance imaging (MRI) and positron emission tomography (PET) – provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. Outsourcing the work to clinical research organisations is proving popular with the world’s largest biopharmaceutical companies that are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzheimer’s and Parkinson’s disease. IXICO reported record annual revenue of £7.6m, up 40 per cent year-on-year, and it’s high value work as gross margins were 6.6 percentage points higher at 65.4 per cent. This meant that gross profit, up 55 per cent to £5m, increased at a faster rate than revenue. So, with a relatively fixed cost base – operating expenses only increased by 14 per cent – IXICO has passed the inflexion point whereby an increasing proportion of gross margin earned from incremental revenue is converted into profit. To put the operational gearing of the business into perspective, IXICO’s operating loss of £0.8m on revenue of £5.4m in 2018 turned into an operating profit of £364,000 on revenue of £7.6m in the 12 months to 30 September 2019. Cenkos had predicted a maiden operating profit of £50,000, so this was a major earnings beat. Moreover, because gross margins are higher than Cenkos had anticipated, and operating costs lower, the broking firm has been forced to upgrade its operating profit estimates by a thumping 70 per cent to £508,000 for the 2019/20 financial year, and by 10 per cent to £1.04m the year after. Forecasts are based on annual revenue rising by 20 per cent to £9m and £10.8m, respectively. However, even the upgraded estimates could prove conservative given that IXICO has increased revenue at a compound annual growth rate of 35 per cent over the past three financial years and continues to win new contracts ('Profiting from artificial intelligence', 28 October 2019). Indeed, the closing order book of £15.9m equates to 80 per cent of the combined revenue forecast for the next two financial years, thus providing a high level of visibility and materially de-risking earnings estimates. IXICO has announced five notable contract wins since August, all of which highlight the value of its core technology and ability to unlock insights on a broad range of neurological disorders and across the full spectrum of clinical development. Interestingly, one of the contracts is focused on a progressive supranuclear palsy (PSP) programme for a new client, ahead of patient enrolment. The 12-month contract, worth £400,000, is expected to lead to a larger programme of work in early 2020, highlighting how the expansion of its services into new therapeutic markets. Another new contract involves a study with an existing client that will see IXICO’s AI technology extended and deployed to several sites in mainland China. Importantly, the company is well funded to maintain its growth trajectory, ending the 2019 financial year with net funds of £7.26m (15.5p a share), a sum equating to 25 per cent of IXICO’s market capitalisation of £31.2m. Strip out net funds, and the company’s enterprise value of £24m equates to 25 times net profit estimates of £947,000 for the 2020/21 financial year. However, if as seems likely IXICO continues to win new contracts, then analysts will be forced again to push through yet more earnings upgrades so that multiple is likely to drop sharply in due course. Buy. We then have no material news for 2 months.... Today Simon says: Aim-traded IXICO (IXI:85p), a London-based company that uses proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans, has delivered a 157 per cent share price gain since I spotted its potential last summer ('Alpha Company Research: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). The share price is up 25 per cent since my last article (‘Playing an earnings upgrade cycle’, 12 December 2019), buoyed by news of a £1.8m extension to a Phase III study in Huntington's Disease, and a £0.6m extension to a study programme in Progressive Supranuclear Palsy. I really like the company and feel that if IXICO continues to win new contracts then analysts will be forced again to push through more earnings upgrades given the operational leverage of the business. However, as it stands right now, the shares trade on 32 times cash adjusted net profit estimates for the 2020/21 financial year and have hit my 85p target price. Take profits. Back to 68p - the same price as his "BUY" Tip last December. Surely he will shortly tell us what a Bargain it is again....
20/8/2019
13:00
mirabeau: With a market capitalisation of £22m, Aim-traded IXICO (IXI:47p) may be under the radar of most investors, but the London-based company is at the forefront of a technological revolution. That’s because the world’s largest biopharmaceutical companies are investing huge sums of money in the field of neurology to target therapies for diseases affecting the central nervous system including Huntington’s, Alzeihmer’s and Parkinson’s disease. This has created a surge in demand for the services of companies that use proprietary artificial intelligence (AI) software algorithms to analyse images from brain scans - magnetic resonance imaging (MRI) and positron emission tomography (PET) – in order to provide measurements of small changes in brain structure, assess the efficacy of new drugs being trialled, monitor patient safety, and provide valuable insights on different aspects of trial performance. In a nut shell, IXICO’s cutting edge proprietary LEAP algorithm harnesses the power of large datasets and computer-based learning to segment specific regions of the brain and then accurately measure their volume, thus providing a reliable method of measuring brain atrophy which can indicate progression of neurological disease. To date the algorithm has been applied to over 150 brain regions, analysed over 100,000 brain scans and has been cited in over 750 scientific publications. The company has also developed AI technology to assess brain pathology like white matter lesions and, more recently, uses data from wearable biosensors to accurately measure sleep patterns in Parkinson’s disease and dementia patients. These approaches enhance the understanding of disease symptoms more directly compared to manual assessment or complex in-clinic technology. Importantly, by applying IXICO’s data science expertise, these measurements have the potential to increase success rates of clients’ clinical trials by improving patient selection, lowering the cost of running them, and reducing the burden on trial participants and their carers by reducing the need for clinic visits. High operational leverage The technology is proving incredibly popular. In fact, no fewer than eight of the 14 top 20 biopharmaceutical companies that have active neurological drug development programmes are clients of IXICO. They clearly hold the company in high esteem as IXICO has booked over £20m worth of new orders since the start of last year, a revenue stream that supports a sustained move to operating profitability. Once that inflexion point is passed, the high gross margin (62 per cent) earned from its cutting edge data analytics activities means that operating profits are set to move sharply higher in the years ahead given the significant amount of automation in the workflow and remote management of the clinical trial imaging sites. This means that IXICO is able to take on additional revenue generating activities without an equivalent increase in staffing costs, the effect of which is that any outperformance against revenue forecasts delivers a high conversion rate of incremental gross margin earned to operating profit. This operational leverage effect is also illustrated by the fact that over the past few years IXICO’s staffing levels have remained between 60 to 70 employees even though revenues earned have more than doubled since 2016. The possibility of profit upgrades was certainly not priced into the company’s valuation when I suggested buying IXICO’s shares, at 33p, in last month’s 8,000 word small-cap report for our Alpha subscribers ('Alpha: Simon Thompson spies opportunity in cutting edge technology', 23 July 2019). It still isn’t for that matter even after the 42 per cent rise in the company’s share price following yesterday’s trading update when management revealed that growth has been accelerated by new and existing contracts coming on line, deployment of newly developed algorithms and faster turnaround times in trial situations. Increased target price To put the current valuation into perspective, analyst Chris Donnellan at house broker Cenkos Securities has torn up his previous estimates and now expects IXICO to post 32 per cent revenue growth in the 2018/19 financial year, and 20 per cent top-line growth in both the 2019/20 and 2020/21 financial years, too. On this basis, IXICO’s annual pre-tax loss is forecast to be slashed from £0.8m to £0.1m on revenue up from £5.4m to £7.1m in the 12 months to 30 September 2019. Furthermore, Mr Donnellan now forecasts that IXICO will generate both an operating and pre-tax profit of £239,000 on revenue of £8.5m in the 2019/20 financial year to produce a net profit of £339,000, rising to an operating and pre-tax profit of £0.88m, and net profit of £0.79m on revenue of £10.25m in the 2020/21 financial year. He had previously forecast a £0.44m operating profit on revenues of £9.55m in the 2020/21 financial year, so the additional £0.7m of revenue that is now expected to be booked that year will produce £0.43m of incremental gross margin, all of which is effectively being converted into operating profit. Cenkos estimate IXICO will have net funds of £5.5m at the end of next month which means that its enterprise valuation of £16.5m equates to 20 times forecast net profits in the 2020/21 financial year, hardly a punchy rating for a highly operationally geared business that is winning new orders and looks to be at the start of an earnings upgrade cycle. Indeed, around two-thirds of the 2020 revenue target is already covered by the contracted order book, so if contract momentum continues to build then it’s not unrealistic to expect IXICO to over deliver even against analysts’ upgraded expectations. In the circumstances, I am raising my 55p target price to 62p, implying a fair value enterprise valuation of £23.5m, in anticipation of the contract momentum in the business continuing to build and the release of another positive pre-close trading update in mid-October. Trading on a bid-offer spread of 45p to 47p, I continue to rate IXICO’s shares a buy.
Ixico share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IXI
Ixico
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 18:00:51